Destiny Pharma Strategy/Company/Ops Update

Brighton, United Kingdom, 17 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces today an update on the considerable progress being made with its late-stage clinical assets, its earlier research programmes and the exciting prospects for the year ahead.

Read more….